Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (14)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  2. Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes

    International Journal of Tuberculosis and Lung Disease, Vol. 18, Núm. 6

2011

  1. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 18, Núm. 5, pp. 325-330

2010

  1. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy

    Antiviral Therapy, Vol. 15, Núm. 6, pp. 881-886

  2. Survival of HIV-infected patients with compensated liver cirrhosis

    AIDS, Vol. 24, Núm. 5, pp. 745-753

2009

  1. Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients

    Clinical Infectious Diseases, Vol. 49, Núm. 9, pp. 1397-1401

2003

  1. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 17, Núm. 7, pp. 1023-1028

  2. Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: Which works better?

    HIV Clinical Trials, Vol. 4, Núm. 4, pp. 244-247

2002

  1. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 6, pp. 438-443

  2. Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir

    AIDS, Vol. 16, Núm. 14, pp. 1964-1966

2001

  1. Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine

    AIDS